drugset / Trial / NCT03976869

A Study to Assess the Pharmacokinetics (PK), Pharmacodynamics (PD) and Safety of 2-Week Treatment With Inhaled AZD7594 in Adolescents (12 to 17 Years) With Asthma

NCT03976869

Phase 1 Completed 36 enrolled AstraZeneca Parexel · collab
NaSingle-groupOpen-labelTreatment

Summary

This is an open-label, multi-centre, Phase I study to assess the PK, PD and safety of 2 week treatment with inhaled AZD7594 in adolescent patients with asthma. The study is planned to be conducted at 4-10 study sites in the United States. The study intends to include 24 patients (12 to 17-year-old patients). For each patient, the duration of participation in the study will be approximately 5 to 7 weeks (37 to 52 days).

Timeline

Start
2019-07-24
Primary completion
2020-07-09
Completion
2020-07-09

Drugs

EvaluationDrugModalityDoseRoute
Subject VELSECORAT Other / unclassified 360 ug Inhaled

Indications